| Primary |
| Metastases To Bone |
28.5% |
| Product Used For Unknown Indication |
25.4% |
| Prostate Cancer |
8.6% |
| Breast Cancer |
6.8% |
| Breast Cancer Metastatic |
6.7% |
| Prophylaxis |
5.9% |
| Prostate Cancer Metastatic |
5.7% |
| Pain |
1.8% |
| Bone Disorder |
1.6% |
| Hypertension |
1.5% |
| Lung Neoplasm Malignant |
1.4% |
| Neoplasm Malignant |
1.2% |
| Osteoporosis |
0.9% |
| Chemotherapy |
0.7% |
| Renal Cell Carcinoma |
0.7% |
| Hypocalcaemia |
0.6% |
| Lung Cancer Metastatic |
0.6% |
| Supplementation Therapy |
0.5% |
| Bone Giant Cell Tumour |
0.5% |
| Hypothyroidism |
0.5% |
|
| Hypocalcaemia |
23.6% |
| Osteonecrosis Of Jaw |
22.4% |
| Death |
14.0% |
| Bone Pain |
4.6% |
| Pain In Jaw |
3.8% |
| Tooth Disorder |
3.8% |
| Hypophosphataemia |
3.4% |
| Dyspnoea |
2.7% |
| Incorrect Route Of Drug Administration |
2.6% |
| Rash |
2.6% |
| Blood Calcium Decreased |
2.2% |
| Neoplasm Malignant |
1.9% |
| Pain |
1.9% |
| Hypercalcaemia |
1.6% |
| Vomiting |
1.6% |
| Fatigue |
1.6% |
| Toothache |
1.5% |
| Hospitalisation |
1.4% |
| Muscle Spasms |
1.4% |
| Paraesthesia |
1.4% |
|
| Secondary |
| Metastases To Bone |
27.1% |
| Product Used For Unknown Indication |
18.3% |
| Prostate Cancer |
13.3% |
| Breast Cancer Metastatic |
6.7% |
| Breast Cancer |
6.3% |
| Prostate Cancer Metastatic |
5.9% |
| Pain |
4.3% |
| Prophylaxis |
3.4% |
| Osteoporosis |
2.3% |
| Lung Neoplasm Malignant |
2.0% |
| Lung Cancer Metastatic |
1.4% |
| Hypertension |
1.2% |
| Chemotherapy |
1.1% |
| Nausea |
1.1% |
| Osteoporosis Postmenopausal |
1.1% |
| Fibrous Dysplasia Of Bone |
1.0% |
| Hypercalcaemia |
1.0% |
| Atrial Fibrillation |
0.9% |
| Breast Cancer Recurrent |
0.9% |
| Bone Disorder |
0.7% |
|
| Osteonecrosis Of Jaw |
22.7% |
| Hypocalcaemia |
13.6% |
| Death |
7.4% |
| Tremor |
5.7% |
| Paraesthesia |
4.5% |
| Spinal Fracture |
4.5% |
| Bone Pain |
4.0% |
| Dyspnoea |
4.0% |
| Muscle Spasms |
4.0% |
| Pain |
4.0% |
| Fall |
3.4% |
| Pain In Jaw |
3.4% |
| Fatigue |
2.8% |
| Rash |
2.8% |
| Tooth Disorder |
2.8% |
| Prothrombin Time Ratio Increased |
2.3% |
| Swelling |
2.3% |
| Toothache |
2.3% |
| Arthralgia |
1.7% |
| Groin Pain |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
50.6% |
| Prostate Cancer |
11.2% |
| Breast Cancer Metastatic |
5.2% |
| Prostate Cancer Metastatic |
4.3% |
| Breast Cancer |
3.9% |
| Metastases To Bone |
3.4% |
| Pain |
3.3% |
| Prophylaxis |
2.9% |
| Nausea |
2.9% |
| Hypertension |
2.3% |
| Supplementation Therapy |
2.1% |
| Constipation |
1.0% |
| Anxiety |
1.0% |
| Bone Disorder |
0.9% |
| Depression |
0.9% |
| Non-small Cell Lung Cancer |
0.9% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Lung Neoplasm Malignant |
0.8% |
| Diabetes Mellitus |
0.8% |
| Chronic Obstructive Pulmonary Disease |
0.7% |
|
| Weight Decreased |
13.7% |
| Vomiting |
8.4% |
| Death |
7.6% |
| Prostatic Specific Antigen Increased |
7.6% |
| Disease Progression |
6.1% |
| Nausea |
6.1% |
| Diarrhoea |
5.3% |
| Respiratory Failure |
5.3% |
| Prostate Cancer |
3.8% |
| Stomatitis |
3.8% |
| Thrombocytopenia |
3.8% |
| Vision Blurred |
3.8% |
| Malignant Neoplasm Progression |
3.1% |
| Pain |
3.1% |
| Pain In Extremity |
3.1% |
| Pneumonia |
3.1% |
| Pyrexia |
3.1% |
| Urticaria |
3.1% |
| Weight Increased |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
|
